Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Dec 30, 2024 · CIK: 1579428
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K on 12/30/24, check for updates.
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on December 30, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial figures or details about the nature of the "Other Events" within the provided text.
Why It Matters
This filing indicates a regulatory update from Axsome Therapeutics, Inc. to the SEC, which may contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a standard SEC form and does not contain specific material non-public information that would immediately impact risk.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- December 30, 2024 (date) — Date of earliest event reported
- 001-37635 (other) — Commission File Number
- 45-4241907 (other) — IRS Employer Identification No.
- One World Trade Center, 22nd Floor (location) — Principal Executive Offices Address
- New York (location) — City of Principal Executive Offices
- 10007 (other) — ZIP Code of Principal Executive Offices
- (212) 332-3241 (phone_number) — Registrant's Telephone Number
FAQ
What specific "Other Events" are being reported by Axsome Therapeutics, Inc. in this 8-K filing?
The provided text for the 8-K filing indicates "Other Events" as an item information, but does not specify the nature of these events.
What is the Commission File Number for Axsome Therapeutics, Inc.?
The Commission File Number for Axsome Therapeutics, Inc. is 001-37635.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 30, 2024.
What is the IRS Employer Identification Number for Axsome Therapeutics, Inc.?
The IRS Employer Identification Number for Axsome Therapeutics, Inc. is 45-4241907.
Where are Axsome Therapeutics, Inc.'s principal executive offices located?
Axsome Therapeutics, Inc.'s principal executive offices are located at One World Trade Center, 22nd Floor, New York, New York, 10007.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-12-30 07:56:30
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20241230.htm (8-K) — 42KB
- axsm-ex99_1.htm (EX-99.1) — 56KB
- axsm-ex99_2.htm (EX-99.2) — 32KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- axsm-ex99_2s1.jpg (GRAPHIC) — 381KB
- axsm-ex99_2s2.jpg (GRAPHIC) — 842KB
- axsm-ex99_2s3.jpg (GRAPHIC) — 233KB
- axsm-ex99_2s4.jpg (GRAPHIC) — 414KB
- axsm-ex99_2s5.jpg (GRAPHIC) — 371KB
- axsm-ex99_2s6.jpg (GRAPHIC) — 373KB
- axsm-ex99_2s7.jpg (GRAPHIC) — 322KB
- axsm-ex99_2s8.jpg (GRAPHIC) — 310KB
- axsm-ex99_2s9.jpg (GRAPHIC) — 266KB
- axsm-ex99_2s10.jpg (GRAPHIC) — 238KB
- axsm-ex99_2s11.jpg (GRAPHIC) — 197KB
- axsm-ex99_2s12.jpg (GRAPHIC) — 227KB
- axsm-ex99_2s13.jpg (GRAPHIC) — 300KB
- axsm-ex99_2s14.jpg (GRAPHIC) — 321KB
- axsm-ex99_2s15.jpg (GRAPHIC) — 290KB
- axsm-ex99_2s16.jpg (GRAPHIC) — 237KB
- axsm-ex99_2s17.jpg (GRAPHIC) — 259KB
- axsm-ex99_2s18.jpg (GRAPHIC) — 289KB
- axsm-ex99_2s19.jpg (GRAPHIC) — 322KB
- axsm-ex99_2s20.jpg (GRAPHIC) — 269KB
- axsm-ex99_2s21.jpg (GRAPHIC) — 376KB
- axsm-ex99_2s22.jpg (GRAPHIC) — 135KB
- axsm-ex99_2s23.jpg (GRAPHIC) — 310KB
- axsm-ex99_2s24.jpg (GRAPHIC) — 357KB
- axsm-ex99_2s25.jpg (GRAPHIC) — 343KB
- axsm-ex99_2s26.jpg (GRAPHIC) — 298KB
- axsm-ex99_2s27.jpg (GRAPHIC) — 166KB
- axsm-ex99_2s28.jpg (GRAPHIC) — 320KB
- axsm-ex99_2s29.jpg (GRAPHIC) — 329KB
- axsm-ex99_2s30.jpg (GRAPHIC) — 365KB
- axsm-ex99_2s31.jpg (GRAPHIC) — 101KB
- 0000950170-24-140949.txt ( ) — 13453KB
- axsm-20241230.xsd (EX-101.SCH) — 23KB
- axsm-20241230_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 30, 2024, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing the results of its ADVANCE-2 and ACCORD-2 trials of the Company's AXS-05 product candidate for the treatment of Alzheimer's disease agitation. The Company will host a conference call at 8:00 a.m. ET on December 30, 2024 to discuss the topline results of these trials. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference. A copy of the presentation that the Company will use in connection with the conference call is filed as Exhibit 99.2 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 30, 2024. 99.2 AXS-05 ADA Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: December 30, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer